Medicare Advantage prescription drug plans that bid below their county benchmark collect a rebate worth 50% to 70% of that gap. CMS's late-July 2026 guidance now requires every rebate dollar routed to Part D to drive the plan's total drug premium to exactly zero, absorbing any surplus through a richer supplemental benefit or an offsetting premium (CMS, July 2026).

Key Takeaways

  • $296.05 is the CY2027 national average monthly bid amount, a 24% increase over 2026 and more than 750% above the $34.71 recorded in 2023, the last full year before the redesigned Part D benefit took effect.
  • Roughly $600 per enrollee per year of rebate money already flows to Part D, about 26% of the $2,400 generated per enrollee across all four spending channels.
  • 79% of individual MA-PD enrollees paid no Part D premium in 2026 against 28% of standalone PDP enrollees, at an $8 average premium against $36 to $44.
  • The rebate pool could shrink 15% under the CY2027 rate notice on Wakely's analysis for AHIP, with dental and vision coverage potentially cut by half. Part D now has a mandatory first claim on it.

How a Bid Below Benchmark Becomes a Rebate Check

Every Medicare Advantage plan submits a bid each June estimating the cost of covering Part A and Part B benefits for a standard enrollee, a deadline the CY2027 cycle kept on its usual first-Monday schedule (Axene Health Partners, 2026). CMS compares that bid to a statutory county-level benchmark, and when the bid lands below it, the difference becomes a rebate the sponsor is legally required to spend on enrollees rather than keep as margin. The spendable share depends on star rating: 70% at 4.5 stars and above, 65% between 3.5 and 4.5 stars, and 50% below 3.5 (KFF, August 2026).

A five-star plan that bids $50 below its benchmark keeps $35 of that gap as spendable rebate; an otherwise identical three-star plan keeps $25 on the same spread. Every dollar must go to one of four channels: buying down the Part B premium, cutting cost sharing, funding supplemental benefits such as dental and vision, or subsidizing the Part D drug benefit bundled into the MA-PD product.

The fourth channel is where the 2027 rule lands. In 2026, sponsors directed roughly $600 per enrollee per year, just over $50 per member per month, into Part D premium buydowns and supplemental drug coverage, out of about $2,400 in total rebate dollars per enrollee (KFF, 2026). That 26% allocation is what funds the near-zero drug premiums MA-PD carriers advertise every Annual Enrollment.

MA-PD (2026)Standalone PDP (2026)
Average Part D premium~$8/month$36-$44/month
Share paying $0 Part D premium79%28%
Rebate dollars available for Part D~$600/enrollee/yearNone; no medical bid to draw from
Federal support beyond standard subsidy$13B in MA rebates directed to Part D$3.6B stabilization demo (ends Dec. 31, 2026)

Nationally, MA rebate dollars financed roughly $13 billion of Part D coverage in 2026, about 3.5 times the $3.6 billion the standalone Premium Stabilization Demonstration cost over the same stretch.

Why the 24% Bid Jump Forces the Reallocation

The CY2027 national average monthly bid amount of $296.05 is a 24% increase over 2026 and more than 750% above the $34.71 recorded in 2023 (Avalere Health, July 2026). The redesign eliminated the coverage gap, capped the annual out-of-pocket maximum at $2,000 for 2025, rising to a proposed $2,400 for 2027, and shifted manufacturer discount obligations into the initial and catastrophic phases.

A larger basic Part D bid widens the gap between that bid and whatever rebate-funded offset an MA-PD sponsor can bring, which is the arithmetic that produces negative basic premiums for plans with strong medical-side bids and high star ratings. CMS will not publish a below-zero premium, so the rule converts that surplus into member-facing benefit rather than letting it sit as sponsor margin.

Sponsors reach zero one of two ways: raise the Part D supplemental premium enough to absorb the negative basic premium on a bid that already carries an enhanced alternative benefit, or add an EA benefit with a new supplemental premium on a bid that does not. CMS's Office of the Actuary walked plan actuaries through the mechanics on a May 14, 2026 Actuarial User Group call led by Jennifer Lazio, FSA, MAAA, including a provision that a sponsor can satisfy the requirement by enhancing the benefit to at least 70% of the Defined Standard Out-of-Pocket-Cost threshold.

The pricing consequence is narrower than it first reads. Pricing and design of the basic and EA benefits lock at the original June submission, so reallocation is a premium-and-margin exercise on a frozen bid, due by 11:59 p.m. Pacific on August 6, 2026. With the rebate pool itself potentially shrinking 15% under the CY2027 rate notice, dental and vision facing cuts of up to half and premiums rising an average of $23 a month (Becker's Payer Issues, citing Wakely for AHIP), pharmacy now carries a compliance floor the medical side does not. The choice is not margin against benefits; it is which supplemental line gets funded.

The Standalone Market Has No Lever, and the LIS Benchmark Moves

A standalone PDP cannot borrow this way. Its entire premium comes out of its own Part D bid, with no adjoining medical bid throwing off rebate dollars, and the Part D Premium Stabilization Demonstration that shielded standalone premiums for two years ends December 31, 2026. The same $296.05 national average bid lands on standalone pricing with no offset at all.

That is the structural reason two products priced against an identical national average produce roughly $8 a month on the MA-PD side against $36 to $44 for a standalone PDP, a gap set to widen once the demonstration's cushion disappears for 2027.

The low-income subsidy benchmark compounds the split. A beneficiary who qualifies pays no premium as long as the plan's premium sits at or below the regional benchmark, a figure calculated separately for the PDP and MA-PD segments and weighted toward each segment's own enrollment and bid mix. MA-PD premiums, already compressed toward zero by rebate dollars and compressed further by the zeroing rule, clear that benchmark automatically more often.

Standalone PDPs, facing the unsubsidized post-demonstration bid, are more likely to land above it. That asymmetry feeds directly into where CMS auto-assigns and re-assigns low-income beneficiaries at the start of the plan year, concentrating those lives further into the MA-PD channel, and the resulting mix shift becomes an input into how both segments price their CY2028 bids.

Further Reading

Sources